The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Abbott Laboratories is a medical devices business with stocks listed in the US. Abbott Laboratories shares (ABT) are listed on the NYSE and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
How to buy shares in Abbott Laboratories
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Abbott Laboratories. Find the share by name or ticker symbol: ABT. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Abbott Laboratories reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Abbott Laboratories, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Abbott Laboratories. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Compare trading platforms to buy Abbott Laboratories shares
Compare other products
We currently don't have that product, but here are others to consider:
How we picked theseFinder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
Have Abbott Laboratories's shares ever split?
Abbott Laboratories's shares were split on a 10000:4798 basis on 1 January 2013. So if you had owned 4798 shares the day before the split, the next day you would own 10000 shares. This wouldn't directly have changed the overall worth of your Abbott Laboratories shares – just the quantity. However, indirectly, the new 52% lower share price could have impacted the market appetite for Abbott Laboratories shares which in turn could have impacted Abbott Laboratories's share price.
Abbott Laboratories shares at a glance
Information last updated 2025-12-01.
| 52-week range | US$109.2106 - US$139.331 |
|---|---|
| 50-day moving average | US$129.3848 |
| 200-day moving average | US$131.0047 |
| Target price | US$144.4292 |
| PE ratio | 16.0817 |
| Dividend yield | US$2.36 (1.83%) |
| Earnings per share (TTM) | US$7.96 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Is it a good time to buy Abbott Laboratories stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is it worth buying Abbott Laboratories stock?
Valuing Abbott Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abbott Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abbott Laboratories's P/E ratio
Abbott Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Abbott Laboratories shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Abbott Laboratories's PEG ratio
Abbott Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.1675. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abbott Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Abbott Laboratories's EBITDA
Abbott Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$11.7 billion (£8.8 billion).
The EBITDA is a measure of a Abbott Laboratories's overall financial performance and is widely used to measure stock profitability.
Abbott Laboratories share price volatility
Over the last 12 months, Abbott Laboratories's shares have ranged in value from as little as US$109.2106 up to US$139.331. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Abbott Laboratories's is 0.719. This would suggest that Abbott Laboratories's shares are less volatile than average (for this exchange).
Abbott Laboratories financials
| Revenue TTM | US$43.8 billion |
|---|---|
| Operating margin TTM | 19.4% |
| Gross profit TTM | US$24.7 billion |
| Return on assets TTM | 6.79% |
| Return on equity TTM | 30.62% |
| Profit margin | 31.88% |
| Book value | 29.303 |
| Market capitalisation | US$222.8 billion |
| EBITDA | US$11.7 billion |
TTM: trailing 12 months
Abbott Laboratories share dividends
Dividend payout ratio: 53.51% of net profits
Recently Abbott Laboratories has paid out, on average, around 53.51% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.84% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Abbott Laboratories shareholders could enjoy a 1.84% return on their shares, in the form of dividend payments. In Abbott Laboratories's case, that would currently equate to about $2.36 per share.
Abbott Laboratories's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Abbott Laboratories's most recent dividend payout was on 16 November 2025. The latest dividend was paid out to all shareholders who bought their shares by 14 October 2025 (the "ex-dividend date").
Abbott Laboratories's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Abbott Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Abbott Laboratories's total ESG risk score
Total ESG risk: 32.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Abbott Laboratories's overall score of 32.35 (as at 12/31/2018) is pretty weak – landing it in it in the 61st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Abbott Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Abbott Laboratories's environmental score
Environmental score: 3.98/100
Abbott Laboratories's environmental score of 3.98 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Abbott Laboratories's social score
Social score: 20.71/100
Abbott Laboratories's social score of 20.71 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Abbott Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Abbott Laboratories's governance score
Governance score: 13.15/100
Abbott Laboratories's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Abbott Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Abbott Laboratories's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Abbott Laboratories scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Abbott Laboratories hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Abbott Laboratories was last rated for ESG on: 2019-01-01.
| Total ESG score | 32.35 |
|---|---|
| Total ESG percentile | 60.66 |
| Environmental score | 3.98 |
| Environmental score percentile | 5 |
| Social score | 20.71 |
| Social score percentile | 5 |
| Governance score | 13.15 |
| Governance score percentile | 5 |
| Level of controversy | 3 |
Abbott Laboratories overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Frequently asked questions
Sources
More resources on Finder
Ask a question
More guides on Finder
-
Best short term investments in Australia for 2025
If you have funds to invest for 2 or years or less, you can safely earn up to 5% p.a. through a high interest savings account, bonds or ETFs.
-
How to buy Washington H. Soul Pattinson and Company shares in Australia
Steps to owning and managing Washington H. Soul Pattinson and Company shares from in Australia.
-
How to invest in copper in Australia
Copper is an industrial metal with many applications. Here’s what you should consider before investing.
-
How to invest in financial stocks in Australia
Financial stocks drive the economy and affect many aspects of a consumer’s economic life.
-
How to buy Viva Energy shares in Australia
Steps to owning and managing Viva Energy shares from in Australia.
-
How to buy Verizon shares in Australia
Steps to owning and managing Verizon shares from in Australia.
-
How to buy Wells Fargo shares in Australia
Steps to owning and managing Wells Fargo shares from in Australia.
-
How to buy Visa shares in Australia
Steps to owning and managing Visa shares from in Australia.
-
How to invest in cannabis stocks
Just 5 years ago, few investors took cannabis stocks seriously; today, as billions of dollars pour into the sector, few doubt that it will be one of the next big disruptors.
-
How to buy Uber shares in Australia
Steps to owning and managing Uber shares from in Australia.